Moreover, the subgroups analysis showed that venetoclax is also effective in FLT3-positive patients and in secondary AML, as well as in TP53-mutated cases (despite the lower incidence—47%—and median duration—5.6 months—of CR). This evidence concerns the gene FLT3 and acute myeloid leukemia.